---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-26-009289"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T01:40:56.180192+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tonix presents TNX-4800 Phase 1 data; plans adaptive Phase 2 field study for Lyme disease prevention in H1 2027

## Summary
- Phase 1 data of TNX-4800 (anti-OspA mAb) for Lyme disease presented at Ticks and Tickborne Diseases Symposium.
- Planned adaptive Phase 2 field study: two-dose SC regimen, primary endpoint 6-month protection; start H1 2027 pending FDA agreement.
- FDA Type C meeting scheduled early Q3 2026 to discuss Phase 2 study design.
- Each fixed subcutaneous dose expected to provide exposure comparable to 5 mg/kg dose in Phase 1.

## SEC filing metadata
- accession: 0001999371-26-009289
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937126009289/0001999371-26-009289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937126009289/tnxp_8k-0422926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-26-009289
- JSON: https://secwatch.observer/filing/0001999371-26-009289.json
- Plain text: https://secwatch.observer/filing/0001999371-26-009289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.